{"classes":[{"categories":[{"measurements":[{"comment":"Not reached","groupId":"OG000","lowerLimit":"8.5","upperLimit":"NA","value":"25.7"},{"comment":"Not reached","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"6.4","upperLimit":"19.5","value":"14.7"},{"comment":"Not reached","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"description":"Progression is defined using the RECIST guideline v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new regional lesions. Local progression is defined as progression within the planning target volume (PTV). Regional progression is defined as progression outside of the PTV but within the same lobe of the lung as the primary tumor or in regional lymph nodes as defined by the American Joint Committee on Cancer (AJCC) 7th edition nodal stations. Local-regional progression-free survival time is measured from the date of randomization to the date of first local-regional progression, death, or last known follow-up (censored). Local-regional progression-free survival rates are estimated using the Kaplan-Meier method. No testing was done due to early study termination.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction erlotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.","id":"OG000","title":"EGFR: Erlotinib"},{"description":"Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.","id":"OG001","title":"EGFR: No Erlotinib"},{"description":"Induction crizotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.","id":"OG002","title":"ALK: Crizotinib"},{"description":"Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.","id":"OG003","title":"ALK: No Crizotinib"}],"paramType":"MEDIAN","populationDescription":"Eligible patients","reportingStatus":"POSTED","timeFrame":"From randomization to study termination. Maximum follow-up was 39.0 months","title":"Local-regional Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}